DelveInsight’s “WHIM Syndrome Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the WHIM Syndrome market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging WHIM Syndrome drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current WHIM Syndrome treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
WHIM Syndrome: An Overview
WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome is an ultra-rare and difficult-to-diagnose primary immunodeficiency disease. In almost all patients of WHIM syndrome, the disease is caused by “gain-of-function” mutations in the single gene that encodes for the CXCR4 receptor.
WHIM syndrome is inherited in an autosomal dominant fashion in familial cases. WHIM syndrome is an extremely rare disease with an incidence of around 0.23 per million births globally. It affects females slightly more than males. According to a research study, 62 females (~60%) and 41 (~40%) males were among 103 probable WHIM patients.
WHIM syndrome is diagnosed by clinical findings like neutropenia, recurrent infections, warts, lymphopenia, bone marrow biopsy (myelokathexis), and CXCR4 gene mutation. However, in real-time clinical practice, timely and accurate diagnosis of WHIM syndrome is challenging, given the heterogeneity and specific nature of the clinical presentation of the disease (warts, hypogammaglobulinemia, and neutropenia).
WHIM Syndrome Market Key Facts
In 2022, the market size of WHIM Syndrome was highest in the US among the 7MM, accounting for approximately USD 4.6 million, which is further expected to increase by 2032.
Among EU countries, France, Italy, and UK account for the maximum market size of USD 0.4, USD 0.3, and USD 0.3 million in 2022 while Spain occupies the bottom of the ladder in the same year with USD 0.1 million.
Japan accounts for a market size of USD 0.29 million in 2022, but these dynamics are expected to change in the forecasted years.
There were 174 diagnosed prevalent cases of WHIM Syndrome estimated to have occurred in the 7MM in 2022 of which 117 of the accounted cases were estimated to be from the US alone.
The age-specific cases of WHIM Syndrome were divided into less than 18 years and 18 years and above, with 91 and 83 cases in the 7MM in 2022.
WHIM Syndrome Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging WHIM Syndrome pipeline therapies. It also thoroughly assesses the WHIM Syndrome market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed WHIM Syndrome drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
WHIM Syndrome Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted WHIM Syndrome epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted WHIM Syndrome epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the WHIM Syndrome Epidemiology, Segmented as –
Total Diagnosed Prevalent Cases of WHIM Syndrome [2019–2032]
Gender-specific Diagnosed Prevalent Cases of WHIM Syndrome [2019–2032]
Age-specific Diagnosed Prevalent Cases of WHIM Syndrome [2019–2032]
WHIM Syndrome Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the WHIM Syndrome market or expected to be launched during the study period. The analysis covers the WHIM Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the WHIM Syndrome drugs based on their sale and market share.
The report also covers the WHIM Syndrome pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key WHIM Syndrome companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the WHIM Syndrome Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/whim-syndrome-market
WHIM Syndrome Therapeutics Analysis
To counter unmet market needs and provide better treatment choices for WHIM Syndrome, several market players are working robustly either on single-agent novel molecules or on combination and dose modification of standard therapies. Several therapies are expected to be launched in the study period, likely to drive market growth during the study period.
Currently, X4 Pharmaceuticals is leading the therapeutics market with its WHIM Syndrome drug candidates in the mid to advanced stage of clinical development.
WHIM Syndrome Companies Actively Working in the Therapeutics Market Include
X4 Pharmaceuticals
National Institute of Allergy and Infectious Diseases (NIAID)
And Many Others
Emerging and Marketed WHIM Syndrome Therapies Covered in the Report Include:
Mavorixafor (X4P-001): X4 Pharmaceuticals – Mavorixafor (X4P-001) is a potential first-in-class, once-daily, oral small molecule, and selective antagonist of the CXCR4 receptor that increases mobilization and trafficking of white blood cells from the bone marrow. The drug is currently in Phase III clinical trials for the treatment of WHIM syndrome in patients aged 12 years or older.
Plerixafor: National Institute of Allergy and Infectious Diseases (NIAID) – National Institute of Allergy and Infectious Diseases is developing plerixafor for the treatment of WHIM syndrome, and the drug has completed Phase III clinical trials.
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. WHIM Syndrome Competitive Intelligence Analysis
4. WHIM Syndrome Market Overview at a Glance
5. WHIM Syndrome Disease Background and Overview
6. WHIM Syndrome Patient Journey
7. WHIM Syndrome Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. WHIM Syndrome Treatment Algorithm, Current Treatment, and Medical Practices
9. WHIM Syndrome Unmet Needs
10. Key Endpoints of WHIM Syndrome Treatment
11. WHIM Syndrome Marketed Therapies
12. WHIM Syndrome Emerging Drugs and Latest Therapeutic Advances
13. WHIM Syndrome Seven Major Market Analysis
14. Attribute Analysis
15. WHIM Syndrome Market Outlook (In US, EU5, and Japan)
16. WHIM Syndrome Companies Active in the Market
17. WHIM Syndrome Access and Reimbursement Overview
18. KOL Views on the WHIM Syndrome Market
19. WHIM Syndrome Market Drivers
20. WHIM Syndrome Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Peripheral Neuritis Market
“Peripheral Neuritis Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Peripheral Neuritis market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Peripheral Neuritis market.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
